We currently subdivide BC by estrogen receptor alpha (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2/neu) status, in part because these markers represent important predictive biomarkers that guide treatment with discernible survival benefits. Here, PGR is linked to breast cancer.